title: Residual disease in chronic myeloid leukemia after induction of molecular remission.
authors.forename: Thoralf
authors.initials: T
authors.lastname: Lange
authors.forename: Dietger W
authors.initials: DW
authors.lastname: Niederwieser
authors.forename: Michael W N
authors.initials: MW
authors.lastname: Deininger
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D016044:Fusion Proteins, bcr-abl / Q000097:blood*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D016133:Polymerase Chain Reaction; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction; D012680:Sensitivity and Specificity
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl